Skip to content

Released May 16, 2022, after the close

10-Q filed May 16, 2022, 46 days after period end · 0000950170-22-010064

Q1 2022 · 10-Q
Revenue$247.00K−96.6% vs Q1 2021no prior Q4 2021 on file
Net Income-$32.80MN/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$1.01N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$30,207,000N/M
Operating Cash Flow-$28,223,000N/M
Margins · derived
Operating margin-12229.6%−11963.8 pt vs Q1 2021
Net margin-13279.4%−13013.6 pt vs Q1 2021

What the release said

The release

Same quarter

MetricQ1 2022Q1 2021Q1 2020Q1 2019
Revenue$247.00K$7.30M$169.00K$3.81M
Net Income-$32.80M-$19.40M-$23.30M-$5.10M
EPS Diluted-$1.01-$0.66-$1.22-$0.29

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR